Research Reports | Market Assessment
April 2014

Breast Cancer (Triple-Negative, Advanced/Metastatic) | Decision Base | US | 2014

What attributes will distinguish emerging therapies in the eyes of oncologists and payers?

Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for treatment with either hormonal or HER2-targeted agents. Treatment typically involves nontargeted cytotoxic chemotherapies. Therefore, great commercial opportunity exists in developing effective, targeted therapies for this patient population. Interviewed oncologists are hopeful that more-effective targeted therapies are on the horizon for this patient population. However, the most promising emerging agents in development for triple-negative breast cancer target only specific subsets of patients, such as those with BRCA1/2-mutation positive disease. As a result, the majority of the triple-negative breast cancer population is likely to remain underserved for the foreseeable future.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports